PD0325901

Licensed by Pfizer 製品コードS1036

PD0325901化学構造

分子量(MW):482.19

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

サイズ 価格(税別)  
JPY 23240.00
JPY 11620.00
JPY 44820.00
JPY 127820.00

文献中の使用例(75)

カスタマーフィードバック(18)

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β, active or total β-catenin Thr202- and Tyr204- phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control; Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways.α -Tubulin was used as a loading control. MAPKi=PD325901.

    Nature, 2018, 553(7686):96-100. PD0325901 purchased from Selleck.

  • c, Examples of CDK2 activity traces aligned to the end of mitosis. Each panel shows different time windows relative to mitosis when mitogens were withdrawn (marked in grey) in d. d, Probability of proliferation (defined as CDK2 activity > 1, 10 h after mitosis) represented as a function of time when inhibitors of MEK (MEKi; 100 nM PD0325901) or of CDK4 (CDK4i; 1 μ M palbociclib) were added or when mitogens were removed, relative to mitosis. Data are mean ± s.e.m. (n = 5 biological replicates).

    Nature, 2017. PD0325901 purchased from Selleck.

    Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

  • Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

    Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

  • (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

    Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

  • Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

     

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

  •  

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

    The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

  • PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

    Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

製品安全説明書

MEK阻害剤の選択性比較

生物活性

製品説明 PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
ターゲット
MEK [1]
(Cell-free assay)
0.33 nM
体外試験

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. [1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. [2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. [2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. [3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell NFiwfIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzPyCwTT6= M{DhS3NCVkeHUh?=
human M14 cell M2TEUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDURXFKdmirYnn0bY9vKG:oIHj1cYFvKE1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFUhdk1w NYXGVIg4W0GQR1XS
human SK-MEL-28 cell MnjRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTJibl2u MVPTRW5ITVJ?
human NOMO-1 cell M4Txbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5QVU9vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFchdk1w NWDsSmJxW0GQR1XS
human A375 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHTTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62PUBvVS5? M4fydnNCVkeHUh?=
human DU-4475 cell NXPKNYtxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE\US|RKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=> M3TCbXNCVkeHUh?=
human C32 cell M2XNWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn20TY5pcWKrdHnvckBw\iCqdX3hckBEOzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[3JI5ONg>? NEW3OnBUSU6JRWK=
human BPH-1 cell NGGyRY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkK2TY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPVUhdk1w M{jqZ3NCVkeHUh?=
human CP50-MEL-B cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NITGd4ZKdmirYnn0bY9vKG:oIHj1cYFvKEOSNUCtUWVNNUJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW4JI5ONg>? M1nrPXNCVkeHUh?=
human H9 cell MlPvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPOTY5pcWKrdHnvckBw\iCqdX3hckBJQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{egcm0v NW\BdXR3W0GQR1XS
human HTC-C3 cell M3H0PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M17BVmlvcGmkaYTpc44hd2ZiaIXtZY4hUFSFLVOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45QSCwTT6= MUfTRW5ITVJ?
human BHT-101 cell Mo\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NILSdlNKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njdibl2u MnH4V2FPT0WU
human COLO-741 cell NUT2eGF7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWLMVlJ1UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc1OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMTDuUU4> MoToV2FPT0WU
human OVCAR-5 cell NX7Q[3ExT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfaWpVNUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py56MjDuUU4> MUfTRW5ITVJ?
human A549 cell NWLuXGd7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIS3NnVKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6KG6PLh?= MoLqV2FPT0WU
human SH-4 cell growth NGnqTGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGDveWpKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3KG6PLh?= M1ThNnNCVkeHUh?=
human SK-N-AS cell NUnhcnJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjVTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVHTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE41PCCwTT6= NIr3SFJUSU6JRWK=
human HT-144 cell M2T6dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfLTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zNESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Mlk4KG6PLh?= MlPuV2FPT0WU
human MEL-HO cell M{S4SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBOTUxvSF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQ6KG6PLh?= MorXV2FPT0WU
human COLO-679 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXXQ[ZE2UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY4QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyLkCxJI5O MVHTRW5ITVJ?
human HuP-T4 cell NXm2[og4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlk5KG6PLh?= NUjwUGdNW0GQR1XS
human H-EMC-SS cell MnH1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvODJibl2u MVfTRW5ITVJ?
human LB2518-MEL cell NXfpZoU{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1y0[WlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{NUG4MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkGzJI5ONg>? NXXQ[ZUxW0GQR1XS
human HL-60 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkfHTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlE2KG6PLh?= NEG1XmxUSU6JRWK=
human NCI-H1666 cell NIe2UndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1mzVWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwMUegcm0v NX;rWmFoW0GQR1XS
human A101D cell NIfqOpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUK1RoFWUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> M4DOUHNCVkeHUh?=
human RVH-421 cell M1fYbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PuSGlvcGmkaYTpc44hd2ZiaIXtZY4hWl[KLUSyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjZ2IH7NMi=> NUT1XnFZW0GQR1XS
human Hs-578-T cell M1LHXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mle1TY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjd7IH7NMi=> MVvTRW5ITVJ?
human A375 cells NWHxWIQ1WHKxbHnm[ZJifGmxbjDhd5NigQ>? MlfIO|IhcA>? NULBVJVmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIV5eHKnc4PpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO|IhcHK|IHL5JGNmdGxidHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVE{KG6PLh?= NX\pNms1OjN2N{SzPFg>
human DOK cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHvTY5pcWKrdHnvckBw\iCqdX3hckBFV0tiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz60JI5ONg>? MoT6V2FPT0WU
human Mewo cell MnnUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJG1mf29iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND60OUBvVS5? NIfONpNUSU6JRWK=
human ONS-76 cell M3LKfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJG9PWy15NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlUyKG6PLh?= MX;TRW5ITVJ?
human UACC-257 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3v3fWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz2yOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC54MjDuUU4> NYezOoIxW0GQR1XS
human SW626 cell NWXuPXFXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlixTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlkyKG6PLh?= NH;sfWxUSU6JRWK=
human SW620 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHwb5JKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvQTVibl2u MU\TRW5ITVJ?
human TYK-nu cell M3S1eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFXOeFNKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjF|IH7NMi=> NFn5O4VUSU6JRWK=
human ACN cell M2fudGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPMT4tKdmirYnn0bY9vKG:oIHj1cYFvKEGFTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlc3KG6PLh?= MXjTRW5ITVJ?
human MIAPaCa2 cells M4HPTXBzd2yrZnXyZZRqd25iYYPzZZk> MmHyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPSVHQZWNiOiClZXzsd{whUUN3ME2xO{BvVS5? NYfzNnVvOjN2N{SzPFg>
human T-24 cell M2PIbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDN[4dXUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPzFibl2u MYHTRW5ITVJ?
human AGS cell NIrCZllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojHTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD60NUBvVS5? NXezXZRMW0GQR1XS
human SW872 cell Ml3kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\OUlFKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvQTlibl2u MX\TRW5ITVJ?
human C2BBe1 cell M2TkWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXjJcohq[mm2aX;uJI9nKGi3bXHuJGMzSkKnMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlU1KG6PLh?= MYPTRW5ITVJ?
human MZ7-mel cell M1\NOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1bPy2vZXygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU41OyCwTT6= NWjNZZdIW0GQR1XS
human HCC2998 cell MnS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fmUmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkm5PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM{NjZ4IH7NMi=> NY\LXGE4W0GQR1XS
human HO-1-N-1 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUexOIpKUW6qaXLpeIlwdiCxZjDoeY1idiCKTz2xMW4uOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN2LkSzJI5ONg>? NFz2OVJUSU6JRWK=
human SW756 cell NIDsSVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLnXYNqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR3IH7NMi=> M3XLWHNCVkeHUh?=
human NCI-H1437 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{W0R2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOFM4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEmgcm0v MXvTRW5ITVJ?
human NCI-H747 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmrjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEe0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1Njl6IH7NMi=> M1r0UHNCVkeHUh?=
human SK-MEL-2 cell NXWzdYZWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{nFcWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PS5{IH7NMi=> NGL2cHJUSU6JRWK=
human MZ2-MEL cell NWnJN|E{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYjBW5lOUW6qaXLpeIlwdiCxZjDoeY1idiCPWkKtUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzVwNkWgcm0v NF;1VWlUSU6JRWK=
human PSN1 cell NG\ufllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PTOmlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO4MlQ2KG6P Mli3V2FPT0WU
human CAL-39 cell NYjhUphxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M176bGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|kvODRibl2u NVzXb3FXW0GQR1XS
human LOXIMVI cell M1Hnemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHPTY5pcWKrdHnvckBw\iCqdX3hckBNV1iLTW\JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|kvOzlibl2u MWPTRW5ITVJ?
human COLO-792 cell NYTZXZcyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17JW2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oy5zNTDuUU4> NFnHWnlUSU6JRWK=
human CAL-27 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnBe5FoUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01PC57MTDuUS=> M{nib3NCVkeHUh?=
human AsPC-1 cell M1PjN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITU[mxKdmirYnn0bY9vKG:oIHj1cYFvKEG|UFOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjJ6IH7NMi=> M{XY[3NCVkeHUh?=
human NCI-H2291 cell NH7ERWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M37FcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlkyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDZwNE[gcm0v NEP2elRUSU6JRWK=
human RCM-1 cell MoXrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn[zTY5pcWKrdHnvckBw\iCqdX3hckBTS01vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS2Mlg2KG6PLh?= NVTPUlRRW0GQR1XS
human NCI-H292 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXqwV5Z5UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR5LkO5JI5ONg>? MUHTRW5ITVJ?
human WM-115 cell NGTZdZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHdONTFzNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS4MlUhdk1w MYrTRW5ITVJ?
human RT-112 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHWzWoxKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ5Njh2IH7NMi=> NWL0WINZW0GQR1XS
human HT-29 cell M4nqNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnHVTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWwMlQ6KG6PLh?= MlP1V2FPT0WU
human RKO cell growth NInCZ|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTV{LkCyJI5ONg>? MofRV2FPT0WU
human KY821 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGHZeVNKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMvOyCwTT6= NUfxbm14W0GQR1XS
human LB1047-RCC cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPZTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTlwNkWgcm0v MmXtV2FPT0WU
human SW1116 cell NGHo[2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH7UWmFKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYxNjR7IH7NMi=> M1TBOnNCVkeHUh?=
human P12-ICHIKAWA cell NUGySWl{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIrJenBKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[yMlI4KG6PLh?= M13zUHNCVkeHUh?=
human HCC70 cell NXHPc4ZrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIrZ[ZlKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{ewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlMvODFibl2u Mln0V2FPT0WU
human MIA-PaCa-2 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fEV2lvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ|LkWzJI5ONg>? MWjTRW5ITVJ?
human LoVo cell NH;XZoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT6yPUBvVS5? MWTTRW5ITVJ?
human LB2241-RCC cell MnW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4jYOmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ3LkWyJI5ONg>? NWfLXnJKW0GQR1XS
human GAK cell Mn63S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfHTY5pcWKrdHnvckBw\iCqdX3hckBISUtiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Nj64O{BvVS5? MXjTRW5ITVJ?
human RD cell MkjlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHJFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwMTDuUU4> MXfTRW5ITVJ?
human KNS-62 cell M1vYXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVnuTVBGUW6qaXLpeIlwdiCxZjDoeY1idiCNTmOtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS57OTDuUU4> MVrTRW5ITVJ?
human HD-MY-Z cell M4PS[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33SZWlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcyNjF{IH7NMi=> MVzTRW5ITVJ?
human COR-L105 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvPzFibl2u MoC3V2FPT0WU
human IA-LM cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmC5TY5pcWKrdHnvckBw\iCqdX3hckBKSS2OTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUezMlI5KG6PLh?= MX3TRW5ITVJ?
human EM-2 cell NGLCe3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGexWmtKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23OE44KG6PLh?= M17Vb3NCVkeHUh?=
human NB69 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfKSGZKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> NVHDTJlHW0GQR1XS
human HuP-T3 cell MlfDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUizMlk{KG6PLh?= Mnf6V2FPT0WU
human BB30-HNC cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1ixNmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05PS53MTDuUU4> NGPaToxUSU6JRWK=
human HT-1080 cell NGfuXZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24OU45QCCwTT6= NV\nZpIxW0GQR1XS
human RMG-I cell M{TTRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;BVYNKdmirYnn0bY9vKG:oIHj1cYFvKFKPRz3JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFcvOzRibl2u NYjadJhRW0GQR1XS
human HCC1419 cell M1nWe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH[2cnFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06OS5|ODDuUU4> M{fKUXNCVkeHUh?=
human SW780 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUKuN|Ihdk1w Mlm2V2FPT0WU
human SNU-387 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYexUZdiUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTNwM{[gcm0> MXnTRW5ITVJ?
human LAMA-84 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDiSWJKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06PC54ODDuUU4> M3LafXNCVkeHUh?=
human MV-4-11 cell NXy1SFBiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\kdHhKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06PC55MzDuUU4> MmnlV2FPT0WU
human EGI-1 cell M{WzWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUWuPFEhdk1w NUXnNplzW0GQR1XS
human NCI-SNU-1 cell NW\lTGJsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXTTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06Pi55MzDuUU4> NH\RfndUSU6JRWK=
human MEG-01 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXW2R21yUW6qaXLpeIlwdiCxZjDoeY1idiCPRVetNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06Py55NzDuUU4> NWHlZZU2W0GQR1XS
human OMC-1 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUf6RXNVUW6qaXLpeIlwdiCxZjDoeY1idiCRTVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOC5{MzDuUU4> NGLCfnRUSU6JRWK=
human NB10 cell NHTRV2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHxTY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCwMlQzKG6PLh?= NH[5Wm9USU6JRWK=
human CAL-62 cell NYixbm9uT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NET6S5NKdmirYnn0bY9vKG:oIHj1cYFvKEODTD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOC55ODDuUU4> M13ibnNCVkeHUh?=
human NCI-H2087 cell MoD5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFjxXWlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyMT6xOEBvVS5? M3uwfXNCVkeHUh?=
human MDA-MB-175-VII cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO|UuXkmLIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYm= M1zEXHNCVkeHUh?=
human LS-513 cell NWft[JU{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYHCVng1UW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwOEOgcm0v MYXTRW5ITVJ?
human HN cell growth NWDBeVFST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn[wTY5pcWKrdHnvckBw\iCqdX3hckBJViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Mj61PUBvVS5? MUXTRW5ITVJ?
human ABC-1 cell NGOyU|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Moj5TY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyN{4xOiCwTT6= NEPvbpZUSU6JRWK=
human SJSA-1 cell MontS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NInDfotKdmirYnn0bY9vKG:oIHj1cYFvKFOMU1GtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOy5zOTDuUU4> M3;TUHNCVkeHUh?=
human PANC1 cells M3\y[mZ2dmO2aX;uJIF{e2G7 MYKxNEDPxE1? NW[4eYZiOSCq MoLNTY5pcWKrdHnvckBw\iCPRVuxJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBxTXKtMT:yJIxmfmWuIHH0JFExKHWPIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> MYGyOVc3PjZ|Mx?=
human MCF7 cells NHe4eHZHfW6ldHnvckBie3OjeR?= MoTMO|UhdWmwcx?= NUTmW3BUUW6qaXLpeIlwdiCxZjDNSYsyNzJiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIHHmeIVzKDd3IH3pcpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? NW\IVpU2OjN|OUi0OVM>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. [2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. [2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. [3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro cascade assay:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: PTC cells
  • 濃度: 0.1 nM- 1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    PTC cells (1 × 104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T0)/(C − T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Ncr-nu/nu mice bearing PTC cells
  • 製剤: 80 mM citric buffer (pH 7)
  • 投薬量: 20-25 mg/kg
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
30% PEG 400+5% Tween 80+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
10mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.19
化学式

C16H14F3IN2O4

CAS No. 391210-10-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumour|Colorectal Cancer University of Oxford|Queens University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall dHebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings November 2014 Phase 1
NCT02096471 Active, not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02022982 Recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 Phase 1
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEKシグナル伝達経路

MEK Inhibitors with Unique Features

相関MEK製品

Tags: PD0325901を買う | PD0325901 ic50 | PD0325901供給者 | PD0325901を購入する | PD0325901費用 | PD0325901生産者 | オーダーPD0325901 | PD0325901化学構造 | PD0325901分子量 | PD0325901代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID